In Latin America, the study of cryptococcosis and its etiological agents has become increasingly important, as this mycosis has significant morbidity and mortality, with more than 5,000 individuals affected with cryptococcal meningitis each year, and 2,400 attributable annual deaths in Latin America alone. The main goal of this review is to present recent and relevant data regarding the studies done in Latin American countries on cryptococcosis and the etiological agents *Cryptococcus neoformans*, and *C. gattii*. Topics related to epidemiology, clinical data and treatment, molecular studies on clinical and environmental isolates, host-pathogen interactions, laboratory data on antifungal susceptibility, preliminary data detecting antigenemia in patients, and studies to search for the environmental niche of the fungus are presented here.

*Epidemiology* - *C. neoformans* is the most important cause of fungal meningitis in the world, and in sub-Saharan Africa, meningeal cryptococcosis is the most common type of meningitis in adults infected with HIV ([@B172]). From a total of 223,100 cases of meningeal cryptococcosis that were estimated to have occurred globally in people living with HIV in 2014, the third largest number of cases in the world were from Latin America, with an estimated incidence of 5,300 cases per year. From those, Brazil and Colombia were the countries with the highest incidence, between 1,001 to 2,500 cases, followed by Argentina and Mexico with an incidence of 501 to 1,000 cases ([@B172]). In particular, an average annual incidence of 4.5 cases of meningeal cryptococcosis per 10^6^ inhabitants was reported in the general population of the state of Rio de Janeiro, Brazil ([@B122]). In Colombia, the average annual incidence of cryptococcosis in the general population has been estimated to be 2.4 cases per 10^6^ inhabitants, while in the HIV-infected population this value has been estimated to be 3,000-3,300 cases per 10^6^ people ([@B131], [@B71]). In addition, [@B129] reported an average annual incidence of 0.0017 cases per 10^6^ in Colombian children.

There is little data regarding the prevalence of cryptococcosis in Latin America. In Mexico, a study of the etiological agents of meningoencephalitis found that the most common mycosis was cryptococcosis, with a prevalence of 10% ([@B20]). In Venezuela, a study of systemic mycoses performed at a national reference centre found that cryptococcosis ranked third with a prevalence of 19%, following histoplasmosis and paracoccidioidomycosis; however, in the population with HIV, *C. neoformans* was isolated in 27% of the cases, following the etiological agent of histoplasmosis ([@B180]). A national survey conducted in Argentina identified cryptococcosis as the second most frequent deep fungal infection with a prevalence of 20%, following that of yeast fungemia ([@B62]). In Mexico, *C. neoformans* had a prevalence of 21% causing fungemia in patients with different types of immunosuppression, only following *Histoplasma capsulatum* ([@B92]). In the same country, cryptococcosis was the third most common invasive fungal infection (13%) found in a highly specialised hospital, following candidiasis and mucormycosis ([@B147]). In Colombia, [@B38] reported cryptococcosis as the most common opportunistic mycosis in patients with HIV/AIDS, with a prevalence of 76%. In the same population in Guatemala, it was estimated that meningeal cryptococcosis is the fourth most common opportunistic fungal infection following candidiasis (esophageal), *Pneumocystis jirovecii* pneumonia, and disseminated histoplasmosis ([@B145]).

In Colombia, among opportunistic infections of the central nervous system (CNS) in patients with HIV, cryptococcosis is the second most common, after toxoplasmosis, which has been demonstrated in clinical studies ([@B127], [@B17]), and autopsies ([@B139]). The same findings have been described in Cuba ([@B118]).

Most cases of cryptococcosis are reported in young HIV positive male patients. Among the HIV negative patients, males are also the predominant sex, although in a smaller proportion, and patients also tend, on average, to be slightly older ([@B65]). This epidemiological distribution has also been found in Latin America ([Table I](#t1){ref-type="table"}). Globally, as in many developing countries, many cases of cryptococcosis in Latin America may not be reported or be confirmed by diagnosis, which in part is reflected by the number of people living with AIDS not in care, undiagnosed, and lost to follow-up, or living in resource-limited areas, which does not allow for a prompt and correct diagnosis ([@B172]).

TABLE ICryptococcosis in Latin America. Epidemiological and clinical dataCountryNumber of casesPercentage of casesReferenceMaleHIV+Clinical presentation (%)HeadacheHigh ICP \> 25 cm H~2~0*C. gattii*LethalityglobalHIV+HIV-ArgentinaBuenos Aires58100100Meningitis (100)88  2121 [@B29]Buenos Aires20417598Meningitis (90)70790.3 40 [@B14]Buenos Aires5888100Meningitis (100)   1919 [@B173]Buenos Aires Province10671100Neuro (91)   3636 [@B151]Chaco (Corrientes)266969Meningitis (96)  0   [@B39]Córdoba (Córdoba)5366100       [@B136]BrazilBahia1046212 93  4312 [@B60]Bahia507052Meningitis (100)9277 (\> 20 cmH~2~O) 22  [@B140]Goiás (Goiânia)627485Meningitis (100)76 6484756[@B100]Mato Grosso do Sul (Campo Grande)1236884Neuro (84)76 10505141[@B126]Mina Gerais (Uberlandia)968081Meningitis (56)  77377 [@B157]Mina Gerais (Uberlandia)418385Meningitis (75)  0586025[@B3]Mina Gerais (Uberaba)1316991Meningitis (79)6053551  [@B153]Río de Janeiro (Rio de Janeiro)6967361Meningitis (96)   5261 [@B122]Rio de Janeiro (Rio de Janeiro)13876100Meningitis (100)   6262 [@B173]Rio Grande do Sul (Porto Alegre)1267795Meningitis (100)80 5   [@B121]São Paulo (São Paulo)987897Meningitis (100)9155 30  [@B211]São Paulo (São Paulo)29550Neuro (86)9676 (≥ 20 cmH~2~O)6421 21[@B134]National, children535324Neuro (96)85 3041  [@B193]BoliviaCochabamba3183100Meningitis (100)23  6767 [@B37]ChileSantiago2893100Meningitis (100)   2121 [@B173]ColombiaNational 1997-20059318378Neuro (96)85 4   [@B131]National 2006-20105267783Neuro (81)8420332  [@B71]Norte de Santander (Cúcuta)907770Meningitis (100)905722344916[@B128]Atlántico (Barranquilla)417678Meningitis (66)  1   [@B162]National, children415824Meningitis (88)78 6   [@B129]Costa RicaSan José717973Neuro (73)100 046460[@B16]CubaLa Habana16820Neuro (100)81  31 31[@B80]EcuadorGuayaquil8273100Meningitis (100)78     [@B189]GuatemalaGuatemala11073100Meningitis (100)80  1414 [@B186]Guatemala6080100Meningitis (100)   4343 [@B146]Guatemala2872100Meningitis (100)93  2121 [@B103]HondurasTegucigalpa2759100Meningitis (100)   3333 [@B173]MexicoCiudad de Mexico3485100Meningitis (100)   3838 [@B173]PanamaPanama2861100Meningitis (100)9657 (≥ 20 cmH~2~O) 5050 [@B96]ParaguayItauguá137662Meningitis (100)90  468320[@B195]PeruLima4787100Meningitis (100)10064 (≥ 20 cmH~2~O)01919 [@B59]Lima9077100Meningitis (100)   4141 [@B28]Lima234 100Meningitis (100)86  2020 [@B46]UruguayMontevideo147 92   0.7   [@B31]VenezuelaCaracas1108383Meningitis (97)   303221[@B168][^4]

*Clinical aspects* - Cryptococcosis mainly affects the CNS, causing meningitis. In a lesser proportion it affects the lungs, and organs such as skin, eyes, prostate, and bone, among others ([@B143]). Classically, patients with meningeal cryptococcosis present a clinical picture consisting of headache and fever, lasting approximately two weeks. Many of these patients also present with nausea, vomiting, cranial nerve involvement, and decreased visual acuity due to intracranial hypertension. If the disease progresses without treatment, mental changes, seizures, and a decreased state of consciousness leading to coma are observed ([@B125], [@B214]). In Latin America, meningeal cryptococcosis is also the main form of clinical presentation, with headache as the cardinal symptom ([Table I](#t1){ref-type="table"}). Intracranial hypertension, one of the most feared complications, has been reported in several Latin American studies, in more than 50% of the cases ([Table I](#t1){ref-type="table"}), which suggests a high percentage of patients with advanced forms of the disease. In autopsy studies conducted in Latin America, patients with neurocryptococcosis, most of whom were infected with HIV, predominantly had disseminated forms of the disease, with multiple organ involvement. Pure meningoencephalitic forms are less frequent, and the presence of cryptococcomas very rare ([@B179], [@B116], [@B139], [@B204]).

*Treatment* - For meningeal cryptococcosis, the treatment of choice recommended by the guidelines of the Infectious Diseases Society of America (IDSA), consists of a combination of amphotericin B deoxycholate (AmBd) 0.7 mg/kg/day, and 5-fluorocytosine (5FC) 100 mg/kg/day for two weeks as induction phase, followed by fluconazole (FCZ) 400 mg daily for eight weeks as consolidation phase, and FCZ 200 mg daily as the maintenance phase. In the induction phase it is recommended to use, as an alternative, the use of liposomal AmB (LAmB) associated (or in combination) with 5FC ([@B169]). In Latin America, due to the unavailability of 5FC and the high cost of LAmB preparations, an alternative regimen recommended by the IDSA for countries with limited resources, with a good level of evidence (AI), consists of AmBd 0.7 mg/kg/day, plus FCZ 800 mg/day for the induction phase of two weeks; followed by FCZ 800 mg per day for eight weeks for the consolidation phase ([Table II](#t2){ref-type="table"}). An alternative scheme for the induction phase is the use of AmBd alone, at a dose greater than 1 mg/kg/day ([@B169]). Similar considerations have been made in the Brazilian ([@B158]), and Colombian ([@B35]) management guidelines.

TABLE IICryptococcosis in Latin America. Clinical presentation and treatmentCountryNumber of casesPercentage of casesReferenceClinical presentation (%)AmBAmB + FCZAmB + 5FCAmB + FCZ or 5FCFCZOtherArgentinaBuenos Aires2041Meningitis (90)100 (1996-2009)100 from 2010100 (1986-1995)   [@B14]Provincia de Buenos Aires106Neuro (91) 100    [@B151]BrazilBahia (Salvador)50Meningitis (100)62320 42[@B140]Mato Grosso do Sul (Campo Grande)123Neuro (84)86   60^*a*^ [@B126]Mina Gerais (Uberlandia)96Meningitis (56)54190 33[@B157]Mina Gerais (Uberlandia)41Meningitis (75)85   75^*a*^ [@B3]São Paulo (São Paulo)29Neuro (86)   100 including LAmB 3[@B134]National, children32 28  66   BoliviaCochabamba31Meningitis (100)100     [@B37]ColombiaNational 1997-2005931Neuro (96)7321   6[@B131]National 2006-2010526Neuro (81)7228    [@B71]Norte de Santander (Cúcuta)90Meningitis (100) 93    [@B128]Atlántico41Meningitis (66)295  17 [@B162]National, children41Meningitis (88)61166339[@B129]Costa RicaSan José71Cerebral (73)7921    [@B16]CubaLa Habana16Neuro (100)6923 8  [@B80]GuatemalaGuatemala110Meningitis (100)78 (15) \*   6 [@B186]PanamáPanamá28Meningitis (100)100     [@B96]ParaguayItauguá13Meningitis (100)857    [@B195]PeruLima47Meningitis (100) 100    [@B59]Lima234Meningitis (100)6225   13[@B46][^5]

The lethality of meningeal cryptococcosis in Latin America has been reported to range from 13% to 73%, with many cases ranging between 30% and 60% ([Table I](#t1){ref-type="table"}), which are very high figures compared to that of the industrialised countries ([@B209]), but similar to those recorded in sub-Saharan Africa ([@B115]). In Brazil, among the systemic mycoses, cryptococcosis causes the highest number of deaths in patients with HIV ([@B171]). In this country, the mortality rate of cryptococcal infections was 0.47 per million inhabitants, and was the thirteenth cause of death ([@B197]). In Colombia, however, the survival rate of patients with meningogenic cryptococcosis has been reported to be 82% for HIV negative patients, and only 46% for HIV positive patients, with a survival time of only four months after diagnosis ([@B128]).

*Molecular studies on C. neoformans and C. gattii* - Several broadly used molecular techniques have been used to determine the genotype of individual isolates, and compare groups of isolates among *C. neoformans* and *C. gattii* species, to carry out molecular epidemiology and population genetics studies. Among these techniques, polymerase chain reaction (PCR) fingerprinting ([@B150]), amplified fragment length polymorphisms (AFLP) ([@B23], [@B99]), microsatellite typing ([@B110]), restriction fragment length polymorphisms (RFLP) ([@B149]), multilocus sequence typing (MLST) ([@B148]), and more recently, whole genome sequencing (WGS) ([@B133], [@B66]), have allowed for the identification of eight major molecular types among the cryptococcal species in the world: VNI (AFLP1) and VNII (AFLP1A/B) for *C. neoformans* var. *grubii* serotype A isolates, VNIV (AFLP2) for *C. neoformans* var. *neoformans* serotype D isolates, VNIII (AFLP3) for hybrids between the serotypes A and D, and VGI (AFLP4), VGII (AFLP6), VGIII (AFLP5) and VGIV (AFLP7) for *C. gattii* serotype B, and C isolates.

Although in most of the studies on *Cryptococcus* and cryptococcosis reported from Latin America, the isolates have been identified only at species level, variety, or serotype; it is now possible to determine the major molecular type of the cryptococcal isolates recovered not only from clinical, but also from environmental sources, and much less frequently from veterinary samples, by using one or more of the above mentioned molecular techniques.

Using these techniques, the major molecular type of 3,486 isolates in Latin America is presently known, with most of the isolates reported from Brazil (45.87%), followed by Colombia (24.99%), Mexico (9.21%), Argentina (8.09%), Cuba (6.05%), Venezuela (2.90%), Peru (1.06%), Ecuador (0.77%), Chile (0.55%), Guatemala (0.43%), as well as Honduras, Paraguay, and Uruguay with one isolate each ([Table III](#t3){ref-type="table"}). From Bolivia, Costa Rica, Dominican Republic, El Salvador, Haiti, Nicaragua, and Panama, there are not data reported about the molecular type of cryptococcal strains.

TABLE IIIDistribution of *Cryptococcus neoformans* and *C. gattii* isolates recovered in Latin America and identified at molecular type levelCountry\*nSource*C. neoformansC. gattii*TotalVNIVNIIVNIIIVNIVVGIVGIIVGIIIVGIVBrazil Clinical69538\--1926918-10391599Environmental30181237215\--555 Veterinary\-\-\-\--5\--5Colombia871Clinical31717-61054392445Environmental2291\--31067611426Mexico321Clinical20921127115267298Environmental18\-\-\-\--5-23Argentina282Clinical2091392311-238Environmental19\-\--23-2-44Cuba211Clinical141\-\-\-\--1-142Environmental68\-\-\-\-\-\--68Veterinary\-\-\--1\-\--1Venezuela101Clinical7661-5103-101Peru37Clinical259-21\-\--37Ecuador27Clinical27\-\-\-\-\-\--27Chile19Clinical4335\-\-\--15Environmental4\-\-\-\-\-\--4Guatemala15Clinical14\-\-\-\--1-15Honduras1Clinical\-\-\--1\-\--1Paraguay1Clinical\-\-\-\-\--1-1Uruguay1Environmental\-\-\-\--1\--1Total Clinical1,7171072522503399092,3593,486Environmental63991233332283111,121 Veterinary\-\-\--15\--6[^6]

From these 3,486 isolates, 67.7%, and 32.2% were recovered from clinical, and environmental sources, respectively. In concordance with global data, the molecular type VNI (AFLP1), corresponding to *C. neoformans* var. *grubii*, serotype A is the predominant molecular type (72.8%) causing cryptococcosis in Latin America, followed by *C. gattii* molecular type VGII (AFLP6) (14.4%) ([Fig. 1](#f01){ref-type="fig"}). Interestingly, in the environment these two molecular types also predominate with slightly different proportions (57.0% for *C. neoformans* VNI, and 28.7% for *C. gattii* VGII) ([Fig. 1](#f01){ref-type="fig"}), although this distribution may be biased by the high prevalence of *C. gattii* VGII in Brazil and Colombia, which are the countries with the largest number of studied isolates ([Fig. 1](#f01){ref-type="fig"}, [Table III](#t3){ref-type="table"}). Of all these studies, only six *C. gattii* isolates (0.2%) have been reported from veterinary cases: one molecular type VGI from Cuba ([@B108]) and five molecular type VGII from Brazil ([@B32], [@B101], da [@B58]) ([Fig. 1](#f01){ref-type="fig"}). Interestingly, in Brazil an outbreak of infection occurred in a breeding aviary in São Paulo, where seven parrot-like birds died of disseminated cryptococcosis. Although the molecular type of the causative agent was not identified, all cases were caused by *C. gattii* serotype B, resistant to FCZ, as determined by biochemical, physiological, and serological testing ([@B176]). To date, veterinary cases of *C. neoformans* have not yet been reported in Latin American countries.

Fig. 1: distribution of *Cryptococcus neoformans* and *C. gattii* identified at molecular type level (n = 3486), recovered from clinical, environmental*a* or veterinary sources in Latin America. Molecular data have been combined from studies reported in Argentina, Brazil, Chile, Colombia, Cuba, Ecuador, Guatemala, Honduras, Mexico, Paraguay, Peru, Uruguay, and Venezuela (Table III). Data from Bolivia, Costa Rica, Dominican Republic, El Salvador, Haiti, Nicaragua, and Panama about the molecular typing of cryptococcal strains has not been reported. *a*: *C. neoformans* has been mostly recovered from avian droppings, decaying organic matter, and soil ([@B33], [@B181], [@B135], [@B182], [@B12], [@B110], [@B200], [@B84], [@B30], [@B36]). *C. gattii* is associated with several tree species ([@B75], [@B206], [@B55], [@B177], [@B74], [@B87], [@B144], [@B13], [@B40], [@B25], [@B210]).

Clinical cases of cryptococcosis from which the major molecular type of the isolates has been identified, date back to 1961 ([@B149]), with most of the studies being retrospective. While Argentina, Brazil, Colombia, and Cuba have described isolates from the 1980s ([@B106], [@B75], [@B110], [@B14]), most of the isolates recovered in Latin America are from the mid-1990s, to date. Case reports, in which *C. gattii* has been isolated as etiological agent, have been documented much more recently ([@B114], [@B159], [@B43], [@B198], [@B163]), with the earliest occurring in 2005 in Brazil ([@B170]). The major molecular type of the environmental isolates was first reported about two decades ago in Cuba ([@B107]), although most of the reports on the molecular types of *C. neoformans* and *C. gattii* from the environment are from after the year 2000.

The combined analysis of the molecular data also showed that in Colombia, the prevalence of the *C. gattii* VGIII is very similar to that of C. *gattii* VGII and that in Mexico, the molecular type VGIII is the most common among *C. gattii* isolates and the second most common after *C. neoformans* VNI. In Argentina however, the most common molecular type among *C. gattii* isolates is VGI ([Fig. 2](#f02){ref-type="fig"}). Mexico is the only country where all major molecular types have been reported, while in Brazil and Argentina only *C. gattii* VGIV seems to be absent and in Colombia only *C. neoformans* VNIII has not been recognised. However, apart from VNIII, the hybrid most commonly found in *C. neoformans*, inter- and intra-specific hybrids have been reportedly for Latin America. One isolate described as the VNII/VNIV hybrid was reported from Argentina, another isolate with the same genotype VNII/VNIV and two isolates VNI/VGII from Brazil, and five isolates VNI/VNII and one isolate VNI/VGII from Colombia ([@B9], [@B8]).

Fig. 2: geographic distribution of *Cryptococcus neoformans* and *C. gattii* isolates from Latin America, identified at the molecular type level (n = 3486). Molecular data have been combined from studies reported in Argentina, Brazil, Chile, Colombia, Cuba, Ecuador, Guatemala, Honduras, Mexico, Paraguay, Peru, Uruguay, and Venezuela (Table III). Data from Bolivia, Costa Rica, Dominican Republic, El Salvador, Haiti, Nicaragua, and Panama regarding the molecular typing of cryptococcal strains have not been reported.

When the mating type of the isolates was identified by specific PCR, the mating alpha was the most common in both *C. neoformans* and *C. gattii* isolates recovered in Latin America, as noted globally ([@B117]). However, in Colombia all *C. gattii* VGIII isolates recovered from *Corymbia ficifolia* detritus, and one VGI isolate recovered from *Ficus* spp. were mating type a ([@B74], [@B87]), as well as 13 clinical and three environmental VGII isolates from Brazil ([@B25], [@B199]), and two VGIII clinical isolates recovered in Mexico ([@B86]). Interestingly, there are no reports on *C. neoformans* mating type a in the region.

The use of MLST and WGS to further advance the understanding of *C. neoformans* and *C. gattii* populations has also been achieved in Latin America. Firstly, a highly clonal population structure of clinical and environmental isolates of *C. neoformans* var. *grubii* was revealed in Brazil ([@B83]), which is in agreement with the clonal evolution and dispersion of *C. neoformans* that has been reported worldwide, these results detail the absence or restriction of genetic recombination, and the persistence of widespread clones. Opposing this, the genetic population structure of many isolates of the less common *C. neoformans* var. *neoformans*, from different geographical origin, including Colombia, and from different sources, showed that this is a highly recombinant population, with the isolates being strictly correlated to each other, and characterised by high variability ([@B45]).

The global diversity of a number of *C. gattii* VGII isolates was also studied, which provided evidence on the evolution of this pathogen in North America and gave support to the extensive evolution in, and dispersal from, South America, most likely from the Amazonia and the Northeastern regions of Brazil, where *C. gattii* VGII strains have shown to have the most genetic variability, compared to isolates from the rest of the world ([@B69], [@B199]).

Additionally, Mexico and Colombia have been proposed to be the likely origins of the VGIII *C. gattii* population, as isolates from these countries are the basal group of isolates recovered worldwide; they are very variable genetically, and have both mating types, which may lead to sexual reproduction and recombination events ([@B86]).

Other molecular techniques employed in Latin American countries have allowed the identification and characterisation of cryptococcal isolates, although without determining the major molecular types. PCR fingerprinting with GACA~4~ primers was used for the genotyping of the first environmental isolate of *C. gattii* recovered in Argentina ([@B150], [@B61]). Electrophoretic karyotyping of 40 *C. neoformans*, and 11 *C. gattii* clinical isolates from Brazil, Chile and Venezuela showed a broad genotypic diversity among the isolates ([@B27]). Sequencing of the internal transcribed spacer (ITS) identified one *C. gattii* isolate recovered from an immunocompetent patient in Chile ([@B198]), and one and five *C. neoformans* environmental isolates recovered from an almond tree in Cuba ([@B112]), and derived from pigeon excreta in Mexico ([@B30]), respectively. In addition, ITS sequencing allowed for the discrimination of an uncommon species causing cryptococcosis, *C. liquefaciens*, in a HIV positive patient from Guatemala ([@B47]). Lastly, using comparative genome hybridisation, the genome content of a clinical *C. neoformans* VNI strain from Argentina was examined, which showed that this strain shared most, if not all, of its genome with H99, the reference strain of *C. neoformans* var. *grubii* ([@B104]).

Diagnostic and identification of cryptococcal species from clinical and environmental samples has also been possible by using molecular methodologies, some of which have been developed in Latin America. PCR of the capsular gene *CAP59,* followed by RFLP was used in Argentina to determine the serotypes of cryptococcal strains directly from a yeast suspension, thus avoiding DNA extraction and making serotype identification quick, simple and inexpensive ([@B194]). In Colombia, a nested PCR targeting the ITS region was developed for the diagnosis of *C. neoformans* and *C. gattii* from human samples, including bronchoalveolar lavage (BAL), bronchial lavage (BL), biopsy, and, cerebrospinal fluid (CSF), showing a sensitivity and specificity of 100% ([@B183]). In addition, in Colombia, two techniques to extract cryptococcal DNA from contaminated soil were standardised, namely glass beads with agarose blocks and an ultra-clean DNA soil kit (MoBio, Solano Beach, CA, USA), which allowed a faster yet specific detection of cryptococcal isolates from soil samples through the amplification of species-specific DNA using the primers CN4 and CN5 ([@B34]). The rapid, sensitive and specific identification of the eight major molecular types, including hybrid strains, from culture and directly from clinical samples is also now possible after the development of a hyperbranched rolling circle amplification of the phospholipase gene *PLB1* in combination with a semi-nested PCR ([@B207]).

Thus, the use of molecular techniques for the study of the etiological agents of cryptococcosis in Latin America, as elsewhere, shows an undoubted value especially for rapid detection and genetic epidemiology studies, and at the same time shows that these methodologies are complementary to traditional techniques.

*Host-Cryptococcus* - The role of *C. neoformans* and *C. gattii* as the major causative agents of fungal meningoencephalitis in humans and animals worldwide ([@B172]) has stimulated more than half-century's worth of investigations on these fascinating and versatile fungi. Nevertheless, many questions about this species and the interactions with the host are not yet fully elucidated, including: (1) whether reactivation of long-term latent infection is a more important cause of cryptococcosis in patients than *de novo* acquisition from the environment; (2) the bases of the preference of some genotypes for certain hosts (i.e. immunosuppressed vs. immunocompetent) and target organs (i.e. brain vs. lung); (3) the mechanism by which the infection becomes persistent and/or recurrent despite that *in vitro* resistance to antifungal drugs does not seem to be a problem for cryptococcal treatment; and (4) the diverse pathways related to sexual reproduction, among many others (Rodrígues et al. 2007).

In Latin American, specifically in Argentina, Brazil and Cuba, different investigations related with these topics have been conducted mostly in order to reveal and comprehend host-pathogen interactions, to investigate the role of interactions between the yeasts and other microorganisms, and to review alternative approaches to antifungal treatments against cryptococcosis and other mycosis. A clear majority of the authors have attempted then to understand the role of the immune cells and the cytokines/antibodies induction not only from human clinical samples but also by using *in vitro* and *in vivo* models.

In AIDS patients with cryptococcal meningitis, cytokine patterns in the CSF and sera were shown to be related to fungal burden and clinical outcome. CSF levels of IL-8, IL-12p40, IL-17A, TNF-α, INF-γ and sera TNF-α were significantly higher among survivors, which indicates that this progressive shift in cytokine expression favouring a Th1 pattern is crucial in controlling cryptococcal infection and would be a prognostic marker in cryptococcal meningitis ([@B155], [@B154]). In addition, the study of the cytokine profile of human peripheral blood mononuclear cells (PBMCs) of healthy individuals, after *in vitro* stimulation with heat-killed *C. gattii* and *C. neoformans* (40 different strains), demonstrated that clinical heat-killed *C. gattii* isolates induced a more pronounced inflammatory response with higher concentrations of pro-inflammatory cytokines (IL-1β, TNF-α and IL-6 and the Th17/22 cytokine IL-17 and IL-22) compared to other *Cryptococcus* species and non-clinical *C. gattii*, which is dependent on TLR4 and TLR9 as cellular receptors ([@B192]).

By using vertebrate models, [@B94], [@B93] showed that in rats, peritoneal eosinophils can migrate into lymphoid organs to act as antigen-presenting cells of *C. neoformans* (strain 102/85) antigens, priming naïve and re-stimulating infected animals to induce T-cell and B-cell responses, and the development of a Th1 microenvironment with increased levels of nitric oxide (NO) synthesis and *C. neoformans*-specific immunoglobulin production, which all lead to a protective immune response against subsequent infection with fungus. Also in rats, the mechanisms involved in macrophage apoptosis promoted by cryptococcal glucuronoxylomannan (GXM) through NO generation showed to be novel immunomodulatory mechanisms that could contribute to limit inflammation during infection in these group of rodents ([@B42]). Obtained from mice, the monoclonal antibodies (mAb) 4B3 were shown to stimulate phagocytosis of the *C. neoformans* (strain 028 LMIPK) by macrophages without fungicidal effect, thus favouring yeast dissemination and decreasing the survival of mice due to cryptococcal infection ([@B95], [@B107]).

In addition to cryptococcosis alone, mouse models have been also used to study the influence of or interaction between other fungi, bacterial and viral agents, and *C. neoformans* and *C. gattii* infections. Fungal-fungal specific interactions between *C. neoformans* and *H. capsulatum*, which co-exist in the environment, that can impact in virulence and disease were investigated. Co-infected mice showed to have significantly higher mortality than infection with *C. neoformans* (strain H99) or *H. capsulatum* alone, or acapsulated strains, as shown by higher pulmonary fungal burden in co-infected animals. Enhanced pellicle formation with a hybrid polysaccharide matrix with higher reactivity to GXM mAbs and increased resistance to phagocytosis and killing by macrophages was also observed, which together indicate that a microbial interaction involving the transfer of virulence traits may translate into enhanced lethality during mixed fungal infections ([@B48]). Secondly, the influence of microbiota in the host response against *C. gattii* (strain L27/01) was demonstrated. Germ-free (GF) mice were more susceptible to infection, showing lower survival, higher fungal burden in the lungs and brain, increased behavioural changes, reduced levels of inflammatory cytokines (IFN-γ, IL-1β and IL-17), and lower NFκBp65 phosphorylation compared to conventional mice, which were associated with smaller yeast cells and polysaccharide capsules in the lungs, and less tissue damage. Moreover, macrophages from GF mice showed reduced ability to engulf, produce reactive oxygen species (ROS), and kill *C. gattii*. Restoration of microbiota in mice that received feces from conventional animals or administration with *Escherichia coli*, made mice more responsive to infection, which was associated with increased survival and higher levels of inflammatory mediators ([@B53]). More recently, the interaction between *C. gattii* infection (strain L27/01) and the concurrent infection with influenza A virus (IAV) strain H1N1 was studied. This co-infection resulted in a major increase in morbidity and mortality, with severe lung damage and a high brain fungal burden when mice were infected in the acute phase of influenza multiplication, indicating that IAV infection is a predisposing factor for severe disease and adverse outcomes in mice co-infected with *C. gattii*. IAV not only alters the host response to the yeast, leading to recruitment of significantly more neutrophils and macrophages into the lungs, but also induces the production of type 1 interferons (IFN-α4/β) and significantly reduces the levels of IFN-γ, which is associated with an impaired immune response. Reduced phagocytosis, killing of cryptococci and production of ROS by IAV-infected macrophages were also shown, leading to increased proliferation of the fungus within macrophages ([@B63]).

*In vitro*, the interaction between antibodies and the cryptococcal capsule, and the effect of protective and non-protective mAbs on *C. neoformans* H99 replication and the capsule's physical properties have been also examined. Protective mAbs were shown to directly alter cell division by trapping and preventing the full release of newly budded cells. This effect is caused by an Ab-mediated increase in capsule stiffness, involving cross-linking of GXM molecules. The ability of mAbs to impair *C. neoformans* budding through changes in the capsule's mechanical properties indicates a new, non-classical mechanism of Ab function, and presents important implications for understanding Ab-mediated immunity ([@B49]). As the interaction between *C. neoformans* H99 and the amoebae is similar to that of the yeast-macrophage association, the participation of fungal virulence-associated structures with *Acanthamoeba castellanii* was evaluated by [@B184]. Fungal extracellular vesicles (EVs) and the GXM were shown to be internalised by *A. castellanii* with no impact on the viability of amoebal cells. However, EVs, but not free GXM, modulate antifungal properties of *A. castellanii* by inducing enhanced yeast survival. Phagocytosis of *C. neoformans* by amoebal cells and the pathogenic potential in a *Galleria mellonella* model are not affected by EVs, but previous interactions with *A. castellanii* rendered fungal cells more efficient in killing this invertebrate host, which all support the notion that interaction of *C. neoformans* with environmental predators results in enhanced virulence ([@B184]).

Both *in vivo* and *in vitro*, the role of mammalian β-galactoside-binding protein Galectin-3 (Gal-3) in *C. neoformans* H99 infection was also revealed. Gal-3 levels no only augments in human sera but also in spleen, lung, and brain tissues of infected mice. Gal-3-deficient mice are more susceptible to cryptococcosis than wild-type animals, as the first group present higher fungal burden and lower animal survival. *In vitro* experiments showed that Gal-3 also inhibits fungal growth and exerts a direct lytic effect on *C. neoformans* EVs, which could benefit the host ([@B4]).

Regarding the research efforts targeting alternative antifungal strategies, [@B18], [@B19] showed that subcutaneous pretreatment of rats with heat killed cells of the *C. neoformans* strain 102/85 (HKC) emulsified in complete Freund adjuvant (CFA), promoted protection against an intraperitoneal challenge with viable *C. neoformans* var. *grubii* with significantly better clearance of yeasts from tissues, a lower concentration of GXM in serum and tissues, and better histopathological parameters compared to un-pretreated infected rats. Passive immunisation with a mAb to glucosylceramides (GlcCer), a lipid that is present at the fungal plasma membrane, cell wall, and secretory vesicles, and which induces antifungal antibodies and regulates the virulence of *C. neoformans* in animal infections, significantly reduced host inflammation and prolonged the survival of mice lethally infected with *C. neoformans* strain 24067 (Serotype D), revealing a potential therapeutic strategy to control cryptococcosis ([@B185]). *In vitro*, mAb-based drugs have shown to be potentially a powerful alternative to standard antifungals, and although *C. neoformans* H99 was reported to be the least susceptible among other fungal species, it was found that wheat germ agglutinin (WGA), linked to the effector Fc region of murine IgG2a (WGA-Fc), was able to inhibit *in vitro* fungal growth, to increase phagocytosis by macrophages, as well as their antifungal functions ([@B124]). Lastly, treatment of *C. neoformans* H99 cells with WGA followed by infection of mice also delayed mortality relative to animals infected with untreated fungal cells. Reduced brain colonisation by lectin-treated cryptococci was also observed. Blocking chitin-like oligomers also rendered yeast cells less efficient in their ability to associate with phagocytes. WGA did not affect fungal viability, but inhibited GXM release to the extracellular space and capsule formation. In WGA-treated yeast cells, genes that are involved in capsule formation and GXM traffic had their transcription levels decreased in comparison with untreated cells ([@B88]).

In this way, the wide variety of approaches and methodologies used in different laboratories from Argentina, Brazil and Cuba have globally contributed to understand particular issues related to the host-pathogen interactions in cryptococcosis.

*Laboratory data: Antimicrobial susceptibility of clinical and environmental isolates* - Most of the data in this topic have been generated on the numerous studies carried out in Brazil and Argentina. The studies have been focused on the methodology and interpretation of the phenotypic tests employed, the susceptibility data generated with clinical and environmental isolates and the study of resistance to some antifungals ([Table IV](#t4){ref-type="table"}).

TABLE IVLatin American studies on the antifungal susceptibility of *Cryptococcus neoformans* and *C. gattii* clinical isolates: methodology, epidemiological cut-off values (ECV), susceptibility patterns, resistance and heteroresistance resultsCountryCommentReferenceArgentinaSusceptibility data for FCZ and AmB for *C. neoformans* isolates from HIV-positive patients[@B15]Correlation of ETest and Neo-Sensitabs diffusion assays with broth microdilution reference method (CLSI-M27-A2) for testing susceptibility of *C. neoformans* to AmB and FCZ[@B164]*In vitro* activity of AmB B by time-kill curve methodology[@B50]International study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for FCZ, ITZ, PCZ, and VCZ. Argentina, Brazil, Cuba, Mexico[@B76]Comparison of different in vitro tests to detect *C. neoformans* not susceptible to AmB[@B52]Susceptibility profile and epidemiological cut-off values of *C*. *neoformans* species complex from Argentina[@B51]*C. neoforman*s lanosterol 14-α-demethylase involved in fluconazole resistance in clinical isolates[@B24]BrazilAn international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for AmB and 5FC in *C. neoformans* and *C. gattii*[@B76]Susceptibility to antifungal agents and genotypes of Brazilian clinical and environmental *C. gattii* strains[@B57]Microbiological characteristics of clinical isolates of *Cryptococcus* spp. in Bahia, Brazil: molecular types and antifungal susceptibilities[@B141]Environmental isolation, biochemical identification, and antifungal drug susceptibility of *Cryptococcus* spp.[@B202]Susceptibility profile of clinical and environmental isolates of *C. neoformans* and *C. gattii*[@B11]A flow cytometry method for testing the susceptibility of *Cryptococcus* spp. to AmB[@B22]*In vitro* susceptibility testing of AmB for *C. neoformans* variety *grubii* AFLP1/VNI and *C. gattii* AFLP6/VGII by CLSI and flow cytometry[@B156]Heteroresistance to ITZ and changes in the morphology and virulence of *C. gattii*[@B82]Antifungal susceptibility of clinical *C. deuterogattii* (AFLP6/VGII) isolates from Southern Brazil[@B102]Resistance to FCZ and changes on virulence and morphological aspects of *C. neoformans* and *C. gattii*[@B187]Antifungal susceptibility testing and genotyping characterization of *C. neoformans* and *C. gattii* isolates from HIV-infected patients[@B85]Evaluation of antifungal combination against *Cryptococcus* spp.[@B178]*C. neoformans* and *C. gattii* isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease[@B160]FCZ non-susceptible *C. neoformans*. Use of LAmB in AIDS patient[@B190]FCZ levels in serum and cerebrospinal fluid[@B191]Time-kill curves studies with AmB against *C. neoformans*/*C*. *gattii* species complex clinical isolatesde [@B63]Heteroresistance to FCZ in clinical and environmental strains of *C. neoformans* and *C. gattii*[@B78]Cuba*C. neoformans*, FCZ susceptibility[@B79]New azoles and *C. neoformans* Cuban clinical isolates[@B109]FCZ, VCZ susceptibility of Cuban isolates[@B113]VenezuelaA review of *C. neoformans* ECVs[@B81][^7]

*Methodology and interpretation of results* - Two reference methods have been used in Latin American studies to determine the minimal inhibitory concentration (MIC), the Clinical Laboratory Standard Institute (CLSI) microdilution method from M27-A3, and the EDef 7.2 from the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Several additional techniques have been developed to simplify the standard ones, such as, time kill curves (TKC), E-Test strips, and a disk diffusion method ([@B164], [@B52], de [@B63]). Recently, the use of flow cytometry (FC) was evaluated in two publications, which both showed a positive significant correlation ([@B22], [@B156]). In one of them, the conclusion was that FC has an excellent correlation with the standard methods, and it is a reliable, fast, and safe method to test the susceptibility to AmB ([@B22]). In the other study, the antifungal susceptibility of 17 clinical isolates of *C. neoformans* and 18 *C. gattii* VGII, was analysed by both the microdilution method (CLSI M27-A3) and FC, showing that FC allowed to determine MIC for AmB in a 2 h incubation time, with MICs data obtained on the same day ([@B156]).

In three additional studies, the epidemiological cut-off values (ECV) for AmB, 5FC, FCZ, itraconazole (ITZ), posaconazole (PCZ) and voriconazole (VCZ), were established ([@B76], [@B77], [@B51]) and recently, a review done by the Venezuelan group was reported ([@B81]). The first two studies were conducted as a part of a collaborative international effort with the participation of Argentina, Brazil, Cuba, and Mexico ([@B76], [@B77]). The rationale of this work was to propose clinical breakpoints for *C. neoformans* and *C. gattii*, according to the molecular types, which was not available, as such EVCs for AmB and 5FC, on basis of MICs (CLSI methodology) were determined. ECVs are commonly used to separate wild-type (WT) isolates from isolates with reduced susceptibility to antifungal drugs with probable acquired resistance mechanisms, are useful to monitor the emergence of strains with mutations that could lead to reduced antifungal susceptibility to antifungal drugs, however they should not be used as predictor of clinical outcome. In the study by [@B51] with Argentinian isolates, the highest ECVs, which included ≥95% of the WT population studied, was observed for 5FC and FCZ (32 µg/mL each), values that were higher than those previously proposed by [@B76], [@B77].

*Clinical and environmental data* - The studies are presented in [Table IV](#t4){ref-type="table"} and the data is variable; hence, it is important to analyse each one of the articles' data, separately ([@B15], [@B113], [@B141], [@B57], [@B11], [@B202], [@B85], [@B102], [@B178], [@B160]).

As a general observation, clinical *C. gattii* strains are more resistant to FCZ in comparison to clinical *C. neoformans* strains. Otherwise, for AmB and 5FC no difference has been reported. Another general observation is that environmental isolates are more susceptible to antifungal drugs than clinical isolates.

It is important to mention the work by de [@B63] describing the phenomenon of tolerance to AmB in some low-MIC strains of *C. neoformans* and *C. gattii*. Clinical studies are warranted to ascertain the relevance of this occurrence as a tool for guide treatment. Additionally, resistance to FCZ was studied by [@B24], in which they found that lanosterol 14-α-demethylase was involved in FCZ resistance in *C. neoformans* clinical isolates. The sequencing revealed the G1855A mutation in three isolates, resulting in the enzyme amino acid substitution G484S. These strains were isolated from two fluconazole-treated patients. Importantly, this mutation would not intervene in the susceptibility to the other widely use azoles, ITZ and VCZ.

*Novel compounds for treatment* - The synthesis of novel compounds has been explored by one research group in Colombia ([@B2], [@B174], [@B152], [@B175]) and by two Brazilian groups (da [@B56], [@B167]) and their preliminary results look promising. Pyrazolonaphthyridines ([@B2]), thiazole-based pyrimido\[4,5-b\] \[1,4\] diazepines ([@B174]), chalcones and N-aryl-2-pyrazolines ([@B152]), and quinolone-based pyrazoles ([@B175]) have shown antifungal activity not only against *C. neoformans* but also against *Candida albicans*, with some of them showing fungicidal, rather than fungistatic activity, which makes them good antifungal candidates.

*Laboratory data: Early diagnosis in HIV patients* - Early diagnosis of cryptococcosis in HIV infected patients has been a topic of interest in Latin America since 1995 ([@B161], [@B132], [@B54]). In all, diagnosis was established with the determination of circulating antigen (CrAg) with the Latex test. Results of the studies were dissimilar but the importance of the CD4+ cells count to increase the sensitivity of the test was established. In 2011, a new CrAg lateral flow assay (CrAg LFA) was developed and preliminary experience in Colombia, Brazil, and Argentina ([@B72], [@B212], [@B91]) showed comparable results to that demonstrated globally ([@B105], [@B213]). That is, a Point-of-Care Test (POCT) like CrAg LFA plays an important role in the early diagnosis of cryptococcosis in HIV patients, especially in resource limited settings. Inclusion of the CrAgLFA in the National Guides for managements of the patients with AIDS must be a compromise of the countries in the region without delay.

*Searching the environmental niche: From avian droppings to tree hollows* - The saprobic nature of the *Cryptococcus* spp. is a well-established fact. Infection with *Cryptococcus* spp. is invariably acquired by exposure to blastoconidia or basidiospores from an exogenous source and the host becomes an accident in the life cycle of the yeast. Consequently, studies on the natural reservoir of *C. neoformans* and *C. gattii* hold paramount interest even though they require a very extensive, programmed, coordinated and sequential field-work. In some Latin-American countries, this search has been conducted for many years. For this review, we will focus on the most recent studies ([Table V](#t5){ref-type="table"}).

TABLE VFindings from recent Latin American environmental studies searching for the niche of *Cryptococcus neoformans* and *C. gattii*CountrySampleSpecies recoveredStudiesReferenceBird excretaTree detritus*C.* *neoformansC. gattii*PhenotypicMolecularArgentinaXXXX**VNI, VGI**[@B177]X X X [@B6] X X **VGI, VGIII**[@B144] XXX **VNI, VGI**[@B40]Brazil XXXX**VNI, VGII**[@B55]X X X**VNI, VNII,** MATa[@B84]XXX X**VNI, VNII**[@B10]X X X [@B201]  XXAS [@B11]X XXAS [@B202] X XX**VGII**[@B13] X XX**VGII**[@B25] XX X**VNI,** MATa[@B36]XXXXAS**VNI, VGII**[@B7]ChileX X AS [@B98] XXX  Toro-Zúñiga et al. (2015)ColombiaXXXXX**VGIII**[@B73]   XX**VGIII**[@B74] X XX**VNI,** **B, VGI, VGIII**[@B87]XXXXX**VNI, VGII, VGIII**[@B138] XX X**VNI**[@B162] XXXX**VNI, VGIII**[@B210]CubaX X  Satellites[@B107] X*Cryptococcus* spp.  [@B112]MexicoX XX XCanónico-Gonzáles et al. (2013)[^8]

The search for the habitat of these yeasts have been successfully achieved in many parts of the world, including Latin America, following Emmons' findings ([@B68]) on the strong association of cryptococci with soil enriched with dry pigeon excreta. Following this, studies on the recovery of the yeasts, not only from pigeon droppings but also from other bird faeces, especially from captive birds, have been successful good in Latin America ([@B6], [@B98], [@B84], [@B10], [@B201], [@B202]). Although most of the isolates therein recovered were identified as *C. neoformans*, VNI, mating type alpha, it is worth mentioning that in one study ([@B202]) *C. gattii* was recovered in 5.2% of samples. Globally, it is known that most of the isolates recovered from bird droppings are *C. neoformans* ([@B117]), with the percentage of recovery varying from place to place from 2% up to 70%.

From the numerous studies done globally on the search for the fungus in avian droppings, it has been very well established that bird droppings shielded from direct sun and ultraviolet light are an excellent substrate for the growth of the yeasts because of their high urea concentrations that is converted to ammonium, and carbamate by the urease enzyme, which is one of the landmark enzymes of the genus.

On the other hand, by the end of the 80s, the natural habitat of *C. gattii* was still unknown, until 1990, when David Ellis and Tania Pfeiffer ([@B67]) published their seminal paper revealing that the habitat of *C. gattii* in Australia was related to *Eucalyptus camaldulensis* trees.

Following the Australian report, recovery of *C. gattii* from *E. camaldulensis* detritus was achieved initially in Mexico ([@B123]) and later in other Latin American countries. However, it is of utmost importance that the work done by Marcia Lazera and her group in Fiocruz, Rio de Janeiro, Brazil, as they demonstrated that the niche of *C. gattii* is not only related with *Eucalyptus* spp. but with an uncountable number of tree species, with isolates recovered especially from tree hollows and decayed woods ([@B119], [@B89]). Importantly, their studies revealed as well that trees are also a habitat for *C. neoformans* ([@B120]), and that sometimes both species are found in the same tree. Those findings encouraged a group in Colombia to search for the habitat of *C. gattii* in a variety of trees and, described, for the first-time, almond trees (*Terminalia catappa)* as the natural habitat of *C. gattii*, serotype C, VGIII ([@B26]). Recently the serotype and molecular type of this species has been isolated form *Tipuana tipu* a native tree from Argentina ([@B144]).

Following Lazera's findings, tree hollows, decayed wood and soil samples have been described as the habitat of *C. gattii*, and *C. neoformans* in a plethora of indigenous and imported trees in some Latin-American countries, including: Argentina ([@B177], [@B144], [@B40]), Brazil ([@B55], [@B10], [@B13], [@B25], [@B36]), Chile (Toro-Zúñiga et al. 2015), Colombia ([@B73], [@B74], [@B87], [@B138], [@B162], [@B210]), and Cuba ([@B110], [@B112]) ([Table V](#t5){ref-type="table"}). Some of the trees genus and species that are the reservoir of *C. gattii* as well as *C. neoformans* are: *E. camaldulensis*, *E. tereticornis*, *Eucalyptus* spp., *Acacia* spp., *Corymbia ficifolia*, *Phoenix* spp., *Tipuana tipui*, *Moquilea tomentosa*, *Cassia grandis*, *Ficus* spp*.*, *Croton* spp*.*, *Cedrus* spp*.*, *T. catappa* and *Tabebuia rosea*.

The rationale for the association of *C. neoformans* and *C. gattii* with decayed wood as a primary ecological niche for both species is that they are lignicolous, the so-called wood decay fungi, due to laccase (diphenoloxidase), an enzyme that oxidizes diphenolic substrates to form long polymers of melanin. Laccase provides protection to the fungus in the environment, and it is one of the most important and most studied virulence factors in *Cryptococcus* ([@B117]).

Environmental isolates have been analysed with some phenotypic and molecular techniques. Antifungal susceptibility has been determined in some of them ([@B11], [@B202], [@B86]) and the results are quite variable. [@B11] reported that 6.2% of the environmental *C. neoformans* isolates were resistant to FCZ. Although in general, clinical isolates have lower susceptibility than environmental isolates to AmB and ITZ and environmental isolates have had lower susceptibility than clinical isolates to FCZ, VCZ, and KCZ, [@B202] reported that all environmental *C. neoformans* isolates were susceptible to the antifungals tested. In addition, [@B86] reported that *C. gattii* VGIII environmental isolates were less susceptible to 5FC, PCZ, VCZ, ITZ and FCZ, and more susceptible to AmB, compared with clinical and veterinary isolates. Clinical isolates of *C. neoformans* were reported to be less susceptible to antifungal drugs than environmental isolates ([@B200]). Although the contribution of these studies is of great importance, more work needs to be done to have enough data for an analysis, especially for the correlation between the source of the isolates, clinical and environmental, and their antifungal susceptibility profiles.

As it was mentioned earlier, molecular studies have been done with some of the environmental isolates, indicated on [Table III](#t3){ref-type="table"} and [Table V](#t5){ref-type="table"}, and the importance of the studies done in Latin America was revealed when the global diversity of the *C. gattii* VGII isolates was studied, and the results provided evidence on the evolution of this pathogen in North American Pacific Northwest and the dispersal from South America, most likely from the Amazonia and the Northeast of Brazil, where *C. gattii* VGII strains have shown to be the most variable genetically ([@B69]).

Many questions about the presence of the fungus in the environment were still without a complete answer, and one of them was related to the survival time of the blastoconidia in the samples. In this way, a couple of studies were carried out in Latin America, and the findings indicated that blastoconidia could remain viable from 45 days up to ten years ([@B5], [@B70]). Efforts have been also made in the design of a culture medium, which use results appropriate for environmental studies to recover the fungus with a major efficiency from the environment ([@B57], [@B5]). It is worth mentioning that the Staib culture medium supplemented with seeds of *Guizotia abyssinica* (niger seeds) is the medium of choice for environmental studies. These seeds provide the substrate for the laccase and the end product is melanin, which is associated with the cell walls and gives the colonies a characteristic brown pigment allowing for the differentiation from other yeast colonies.

Related to *C. gattii*, the pioneer environmental studies that have been done in Latin America and the ongoing ones with the assistance of molecular tools will allow to understand more clearly the expansion of the ecological niche of this species.

Particularly in Colombia, a study on ecological niche modelling was also used to forecast the distribution of cryptococcal species and to produce risk area maps for cryptococcal disease in the country ([@B138]). This study was conducted following the success of accurately identifying ecological niche areas of human and animal cases of *C. gattii* in British Columbia, Canada ([@B137]) and also complements the report on niche prediction of *C. neoformans* and *C. gattii* in Europe ([@B44]). As ecological niche modelling is a great tool to very likely predict where these pathogenic yeasts survive in the environment and therefore to identify areas with high risk of infection, it would be relevant to conduct such studies in all Latin-American countries, in order to increase awareness of this disease in regions at risk of environmental colonisation of *C. neoformans* and *C. gattii*.

*Concluding remarks* - The study of cryptococcosis and its etiological agents have been taking place in several Latin-American countries for several years and because of this, significant progress has been made on topics such as clinical epidemiology, laboratory identification and typing of cryptococcal strains, searching, and understanding the environmental niche, and recently, on the basic biology and population genetics of *C. neoformans* and *C. gattii*.

*Key points* - (i) globally, *C. neoformans* molecular type VNI, causes more than 90% of the cases of cryptococcosis in Latin America and the main risk factor for acquiring it (70-90%) is to be infected with HIV. *C. gattii*, VGII and VGIII, are also recovered, affecting otherwise healthy individuals; (ii) AmB and FCZ are the antifungal drugs of choice, since 5FC is unavailable in the region; (iii) laboratory diagnoses and species or molecular type identification are performed with the standardised protocols; (iv) determination of the antifungal susceptibility shows that in 90% of cases, both species are susceptible to the antifungals tested, namely: AmB, 5FC, FCZ, PCZ, VCZ, and ITZ. Particularly, *C. gattii* VGIII, serotype C isolates have shown decreased susceptibility to azoles, especially to FCZ; (v) molecular studies of clinical and environmental isolates show that in Latin America, *C. neoformans,* molecular type VNI, is not only predominant among the clinical cases, but also in the environment, followed by *C. gattii* molecular type VGII, with similar proportions in both clinical-, and environmental sources; (vi) a great amount of information is from the Latin American studies on the environmental niche, especially for *C. gattii*; (vii) the increasing application of genotyping methods in Latin America, has also greatly contributed to the global study of *C. neoformans* and *C. gattii*, to the recognition of their great inter-, and intra-species genetic diversity, to understand how these pathogenic yeasts have spread around the world and what is their population structure, and to better define some disease aspects of cryptococcosis, an important mycosis in the region.

To Professor Wieland Meyer, from the University of Sydney Australia, for the collaborative work of many years done under his guide, resulting in many of the articles presented in this review.
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